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Cystic fibrosis is a genetic disease usually diagnosed by abnormal sweat testing. We report a case of an 18-year-old
female with bronchiectasis, chronic P. aeruginosa infection, and normal sweat chloride concentrations who experienced
rapid decrease of lung function and clinical deterioration despite treatment. Given the high suspicion ofcystic fibrosis,
broad genotyping testing was performed, showing a compound heterozygous with ∆F508 and 3849+10kb C→T mutations,
therefore confirming cystic fibrosis diagnosis. Although the sweat chloride test remains the gold standard for the diagnosis
of cystic fibrosis, alternative diagnostic tests such as genotyping and electrophysiologic measurements must be performed
if there is suspicion of cystic fibrosis, despite normal or borderline sweat chloride levels.
DESCRIPTORS: Cystic fibrosis. Atypical. Diagnosis. Sweat chloride. Mutations.
Cystic fibrosis (CF) is the most
common lethal genetic disease in Cau-
casians and is characterized by chronic
and recurrent lung infections, pancre-
atic insufficiency, and high chloride
levels in the sweat. Inheritance is au-
tosomal recessive, and the disease is
caused by mutations in the cystic fi-
brosis transmembrane conductance
regulator (CFTR) gene, located in the
long arm of chromosome 7. As for
many other human monogenic dis-
eases, high variability in disease ex-
pression is found among patients. The
sweat test has been the diagnostic
“gold standard” for CF since its de-
scription in the late 1950s, but now it
is clear that a few patients (1% to 2%)
may have normal or borderline sweat
chloride concentrations, a condition
associated with some specific muta-
tions. Such patients have mild CF vari-
ants that include atypical clinical
manifestations; therefore, it is recom-
mended that they should be referred
for CFTR genotyping1,2. Although
nowadays this is common knowledge
among CF caregivers, there are few
publications of case reports of CF with
normal sweat chloride levels, and gen-
eral pediatricians are usually not aware
of this possibility. Searching PubMed
using the following keywords: [cystic
fibrosis] and [normal] and [sweat chlo-
ride] and [case report] we found 21 en-
tries. Of these entries, 8 were case re-
ports that share some similarity to ours,
but 2 cases were not confirmed by ge-
netic testing.
In Brazil, CF is an underdiagnosed
condition that is primarily treated at
specialized centers, usually university
hospitals. The Pediatric Pulmonology
Unit of the Children’s Institute is a gen-
eral pediatric pulmonology clinic that
treats approximately 120 CF patients.
Cystic fibrosis is routinely diagnosed
by clinical symptoms and sweat test-
ing; genotyping was not routinely per-
formed before 1998 except for selected
or atypical cases. We report a case of a
female with symptoms suggesting CF
but with normal sweat chloride levels
who underwent genotype testing that
confirmed the CF diagnosis.
CASE  REPORT
An 18-year-old female was referred
to our service in 1997 with a previous
history of atopic symptoms, such as al-
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lergic rhinitis and angioneurotic
edema, as well as nasal polypectomy
at age 9. There was no history of pneu-
monia, although she presented several
upper airway infections, treated with
antibiotics, expectorants, and antihis-
tamines. Her brother was healthy, and
no relative had experienced similar
symptoms. She was well until age 16,
when adynamia, chronic cough, and
dyspnea during exercise ensued. Her
pulmonary symptoms worsened, and
the cough became productive. During
this period, salivary gland lithiasis was
diagnosed, with spontaneous resolu-
tion. The patient was referred for evalu-
ation showing mild malnutrition with-
out clinical steatorrhea, finger club-
bing, and diffuse inspiratory crackles
at pulmonary auscultation. A chest X-
ray revealed hyperinflation and bron-
chiectasis, confirmed by chest CT scan.
Sweat chloride measurements by pilo-
carpine iontophoresis ranged from 23
to 47.5 mEq/liter (5 samples). A spu-
tum culture was positive for Staphylo-
coccus aureus. Pulmonary function
testing revealed an obstructive disor-
der, with a forced vital capacity (FVC)
of 2.28 L (68%) and a forced expira-
tory volume in the first second (FEV1)
of 1.71 L (52%). Genotyping identi-
fied a ∆F508 mutation in 1 allele. Pan-
creatic function was assessed by a 72-
hour fecal fat study and was found to
be preserved.
The patient developed chronic S.
aureus and intermittent Pseudomonas
aeruginosa pulmonary infection. Acute
pulmonary exacerbations were treated
with oral or intravenous antibiotic
therapy. Despite aggressive treatment,
pulmonary function testing revealed a
massive decrease in FVC and FEV1
(0.82 L (25%) and 1.30 L (32%), re-
spectively) after 2 years. A new chest
CT scan was performed and showed
widespread bronchiectasis and large
cysts, mainly in the upper lobes (Fig.
1). Since the clinical presentation sug-
gested CF, in spite of repeatedly nor-
mal sweat chloride values, a new
broader genetic testing including in-
frequent mutations was performed. The
new genotyping showed that the pa-
tient was a compound heterozygous,
with ∆F508 and 3849+10kb C→T mu-
tations, which confirmed the diagno-
sis of CF. The basic treatment of CF
was maintained with nutritional sup-
port, frequent courses of systemic an-
tibiotics, and continuous inhaled
gentamycin; however, lung function
decline persisted, and the patient is
now waiting for a lung transplantation.
DISCUSSION
The concept of “mild” and “se-
vere” mutations was proposed by
Kerem et al.3 as an explanation for the
clinical heterogeneity of CF. However,
because of the high clinical variabil-
ity and the large number of identified
mutations, it is very difficult to char-
acterize genotype-phenotype correla-
tions in CF, except for the most com-
mon mutations. The ∆F508 mutation
is usually associated with a more se-
vere clinical presentation and higher
sweat chloride levels, while a few other
mutations are associated with a mild
phenotype. Patients carrying at least 1
mild mutation may present symptoms
with later onset, better nutritional sta-
tus, pancreatic sufficiency, and lower
sweat chloride levels 2.
Highsmith et al.4, studying 23 pa-
tients with pulmonary disease charac-
teristic of CF but with normal sweat
testing, identified a point mutation in
intron 19 of the CFTR gene, termed
3849+10kb C→T. Published data
show mild phenotypic characteristics
among CF patients who are ho-
mozygous for this mutation. The on-
set of pulmonary disease was delayed
in most of them, but then became se-
vere in some, as was the case for our
patient. Male patients can have normal
sperm count, sweat Cl- values are usu-
ally in the intermediate or normal
range, and sufficient exocrine pancre-
atic function is reported1,5. The Cystic
Fibrosis Genetic Analysis Consortium
reports the relative frequency of the
3849+10kb C→T mutation to be
1.4%1.
A classification system according
to the functional properties of the gene
product was proposed by Welsh and
Smith6. Class V mutations result in re-
duced synthesis of normally function-
ing CFTR because of defective
processing or alternative splicing sites,
resulting in decrease of normal mes-
senger ribonucleic acid (mRNA) tran-
scripts7. The 3849+10kb C→T muta-
tion produces an alternative splicing
site, and decreased amounts of CFTR
Figure 1 - High resolution computer tomography scans showing diffuse bronchiectasis and
large cysts in upper lobes.
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mRNA can be detected4. Minor disease
manifestations are probably associated
with some production of normally
functional protein. Patients with the
3849+10kb C→T mutation appear to
have less significant pulmonary dis-
ease than patients homozygous for
∆F508, although lung disease is the
most severe clinical manifestation re-
ported1,4. In compound heterozygous
patients, the presence of the ∆F508 al-
lele does not necessarily confer a more
severe prognosis3.
Although in most patients with CF
all major diagnostic criteria are present,
variation in severity of involvement of
the different organs is well known.
Chronic pulmonary disease, even in the
absence of pancreatic insufficiency and
abnormal sweat electrolyte values, can
suggest CF if other clinical manifesta-
tions like nasal polyposis, azoospermia,
or mucoid P. aeruginosa colonization
is present. For more than 30 years, the
sweat chloride test has been used to
confirm the diagnosis of CF and re-
mains the gold standard8. However,
once there is a clinical suspicion of CF
but normal or borderline sweat chloride
levels, alternative diagnostic tests such
as genotyping and electrophysiologic
measurements must be performed to
confirm diagnosis.
RESUMO
SILVA FILHO LVF e col. - Fibrose
cística com dosagem de cloro no
suor normal – relato de caso. Rev.
Hosp. Clín. Fac. Med. S. Paulo 58
(5):260-262, 2003.
A fibrose cística é uma doença ge-
nética usualmente diagnosticada atra-
vés de teste anormal de dosagem de
cloro no suor. Os autores descrevem o
caso de uma paciente de 18 anos com
bronquiectasias e infecção crônica por
P. aeruginosa mas com dosagens de
cloro no suor normais que evoluiu com
rápido declínio da função pulmonar e
piora clínica, a despeito do tratamen-
to. Dada a forte suspeita de fibrose
cística, realizou-se um teste de genoti-
pagem amplo, evidenciando a presen-
ça de mutações ∆F508 e 3849+10kb
C→T, deste modo confirmando o di-
agnóstico de fibrose cística . Apesar da
dosagem de cloro no suor ainda ser
considerada o padrão ouro para o di-
agnóstico de fibrose cística , testes di-
agnósticos alternativos como geno-
tipagem e medidas eletrofisiológicas
devem ser empregados se há suspeita
de fibrose cística , mesmo com níveis
normais ou limítrofes de níveis de clo-
ro no suor.
DESCRITORES: Fibrose cística.
Atípica. Diagnóstico. Cloro no suor.
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